IDH1 and cholangiocarcinoma: Subsequently, ivosidenib, developed by Agios Pharmaceuticals against IDH1 mutations, was approved by the FDA for the treatment of AML and cholangiocarcinoma with IDH1 mutation.1298 Moreover, AG-881 is undergoing clinical trials for the treatment of AML-carrying IDH2 or IDH1/2 mutations (NCT02492737).